In this study, we leverage a large, diverse, national cohort of previously screened men as they turned 70 years to examine the value of PSA values, race and ethnicity, and competing mortality risk in identifying those at elevated risk of PCSM and metastatic prostate cancer (mPCa) who might preferentially benefit from continued screening. This evidence concerns the gene KLK3 and metastatic prostate carcinoma.